Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

27%

3 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 2
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 3(2)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT04902573Completed

A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes

Role: collaborator

NCT06100042Active Not Recruiting

Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting

Role: collaborator

NCT06488625Phase 2Recruiting

Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients with Mild to Moderately Active Ulcerative Colitis

Role: collaborator

NCT06567977Recruiting

TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients

Role: collaborator

NCT04552327Phase 3Completed

5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis

Role: collaborator

NCT05728749Unknown

A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes

Role: collaborator

NCT04398758Phase 3Unknown

Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood

Role: collaborator

NCT04024579Completed

Treatment of Actinic Keratosis With 5% KOH Solution

Role: collaborator

NCT01142453Completed

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Role: collaborator

NCT01142557Completed

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Role: collaborator

NCT01142466Phase 4Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone

Role: collaborator

All 11 trials loaded